Results 211 to 220 of about 205,975 (308)

Understanding the Epidemiology of Pertussis in Denmark

Acta Paediatrica, EarlyView.
Tine Dalby, Aoife Ronayne, Peter Henrik Andersen   +2 more
wiley   +1 more source

Newly identified properties of known pharmaceuticals and myxobacterial small molecules revealed by screening for autophagy modulators

The FEBS Journal, EarlyView.
Autophagy is a cellular degradation process involved in, for example, immune responses to pathogens and neurodegeneration. To identify modulators of autophagy, we developed a microscopy‐based screening assay and identified previously unknown autophagy‐modulating activities in known drugs and natural products from myxobacteria and fungi.
Janine Fichtner, Yan Yan Beer, H. G. Mauricio Ramm, Sabrina Mühlen, Frank Surup, Jennifer Herrmann, Toni Luise Meister, Stephanie Pfaender, Ursula Bilitewski, Mark Brönstrup, Rolf Müller, Manfred Wirth, Eeva‐Liisa Eskelinen, Ingo Schmitz   +13 more
wiley   +1 more source

Utilisation of monoclonal antibodies in the single radial immunodiffusion assay to determine potency and stability for seasonal and pandemic influenza vaccines. [PDF]

Front Immunol
Bodle J, Burge D, Gounder G, Vandenberg K, Laurie K, Rockman S.   +5 more
europepmc   +1 more source

Post‐marketing safety of CGRP monoclonal antibodies and gepants: A systematic review of spontaneous reporting system data

Headache: The Journal of Head and Face Pain, EarlyView.
Abstract Objective Calcitonin gene‐related peptide (CGRP) inhibitors, including monoclonal antibodies (mAbs) and small‐molecule antagonists (gepants), have transformed migraine treatment. Although clinical trials established their efficacy and initial safety, post‐marketing surveillance is essential for understanding their real‐world safety profile in ...
Martina Giacon, Salvatore Terrazzino
wiley   +1 more source

First Among Equals: The Case for High-quality Clinical Data in Influenza Vaccines. [PDF]

Clin Infect Dis
Manning JE, Beckers F, de Bruijn I, Sridhar S, Gurunathan S.   +4 more
europepmc   +1 more source

Age at First RSV Hospitalisation and the Risk of Subsequent Bacterial Pneumonia

Acta Paediatrica, EarlyView.
Samuel Videholm, Karin Strandell, Maria Björmsjö, Andreas Tornevi, Sven Arne Silfverdal   +4 more
wiley   +1 more source

Age‐related differences in mRNA vaccine immunogenicity and adjuvancy

Immunology &Cell Biology, EarlyView.
Older people often respond poorly to mRNA vaccines, with reduced T and B cell responses, but they also bear more morbidity and mortality for infectious diseases. This paper maps age‐related changes in mechanisms of adjuvancy that can shape the immunogenicity of mRNA vaccine in a mouse model. Created in BioRender.
Shivali Savita Chinni, Gemma S Trollope, Patrick Leung, Jonathan L McQualter, Chee Wah Tan, Linfa Wang, Leonard Lim, Adam K Wheatley, Jennifer A Juno, Stephen J Kent, Hareth A Al‐Wassiti, Colin W Pouton, Kylie M Quinn   +12 more
wiley   +1 more source

Low-level human memory T and B cells recognising avian influenza hemagglutinins are poorly responsive to existing seasonal influenza vaccines. [PDF]

Clin Transl Immunology
Gonelli CA, Koutsakos M, Esterbauer R, Zheng MZ, Liu YC, Zin AK, Schwab LS, Hurt AC, Kent SJ, Juno JA, Wheatley AK.   +10 more
europepmc   +1 more source

Tissue Resident Memory Cells: Friend or Foe?

Immunology, EarlyView.
Tissue‐resident memory T cells (TRM cells) are specialised immune cells in barrier tissues like the lungs, skin and gut, providing rapid host defence and tumour surveillance. Their retention and differentiation are regulated by molecules such as CD69, CD103 and TGF‐β. Dysregulation of TRM cells can lead to chronic activation, driving conditions such as
Chidimma F. Chude, Jude E. Uzonna, Janilyn Arsenio   +2 more
wiley   +1 more source

Accomplishments and challenges in developing improved influenza vaccines: An evaluation of three years of progress toward the milestones of the influenza vaccines research and development roadmap.

Vaccine
Ostrowsky JT, Vestin NC, Mehr AJ, Ulrich AK, Bigalke L, Bresee JS, Friede MH, Gellin BG, Klugman KP, Nakakana UN, Wang TY, Weller CL, Osterholm MT, Lackritz EM, Moore KA, Influenza Vaccines R and D Roadmap Taskforce.   +15 more
europepmc   +1 more source